JP2015514115A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514115A5
JP2015514115A5 JP2015504730A JP2015504730A JP2015514115A5 JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5 JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
polypeptide
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015504730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514115A (ja
JP6234993B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/035305 external-priority patent/WO2013152213A1/en
Publication of JP2015514115A publication Critical patent/JP2015514115A/ja
Publication of JP2015514115A5 publication Critical patent/JP2015514115A5/ja
Application granted granted Critical
Publication of JP6234993B2 publication Critical patent/JP6234993B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015504730A 2012-04-06 2013-04-04 赤血球を増加させるための方法および組成物 Expired - Fee Related JP6234993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621154P 2012-04-06 2012-04-06
US61/621,154 2012-04-06
PCT/US2013/035305 WO2013152213A1 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017144654A Division JP2017190344A (ja) 2012-04-06 2017-07-26 赤血球を増加させるための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015514115A JP2015514115A (ja) 2015-05-18
JP2015514115A5 true JP2015514115A5 (enExample) 2016-06-02
JP6234993B2 JP6234993B2 (ja) 2017-11-22

Family

ID=49301055

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015504730A Expired - Fee Related JP6234993B2 (ja) 2012-04-06 2013-04-04 赤血球を増加させるための方法および組成物
JP2017144654A Withdrawn JP2017190344A (ja) 2012-04-06 2017-07-26 赤血球を増加させるための方法および組成物
JP2019123059A Withdrawn JP2019156858A (ja) 2012-04-06 2019-07-01 赤血球を増加させるための方法および組成物
JP2021077695A Pending JP2021107453A (ja) 2012-04-06 2021-04-30 赤血球を増加させるための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017144654A Withdrawn JP2017190344A (ja) 2012-04-06 2017-07-26 赤血球を増加させるための方法および組成物
JP2019123059A Withdrawn JP2019156858A (ja) 2012-04-06 2019-07-01 赤血球を増加させるための方法および組成物
JP2021077695A Pending JP2021107453A (ja) 2012-04-06 2021-04-30 赤血球を増加させるための方法および組成物

Country Status (6)

Country Link
US (4) US9809636B2 (enExample)
EP (2) EP3351260B1 (enExample)
JP (4) JP6234993B2 (enExample)
AU (3) AU2013243388B2 (enExample)
CA (1) CA2869474C (enExample)
WO (1) WO2013152213A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
SI3286206T1 (sl) 2015-04-22 2021-07-30 Biogen Ma Inc. Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
KR100255415B1 (ko) 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP1863518A2 (en) 2005-03-30 2007-12-12 Wyeth Methods for stimulating hair growth by administering bmps
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008076437A2 (en) 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ, インコーポレイテッド アクチビン−ActRIIa拮抗薬およびFSH分泌を低減または阻害するための使用
EP2265603B1 (en) * 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
KR20190128254A (ko) 2008-05-02 2019-11-15 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 alk1 길항제 기재의 방법 및 조성물
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
KR20110031951A (ko) * 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
CN102655872B (zh) 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
JP2012238811A (ja) 2011-05-13 2012-12-06 Toshiba Corp 半導体不揮発性記憶装置およびその製造方法
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN104411720B (zh) * 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
JP6976859B2 (ja) 2015-05-13 2021-12-08 セルジーン コーポレイション ActRIIリガンドトラップを用いたβ−サラセミアの治療

Similar Documents

Publication Publication Date Title
Merten et al. Viral vectors for gene therapy and gene modification approaches
JP2017533910A5 (enExample)
JP2015518818A5 (enExample)
JP2014512171A5 (enExample)
JP2014513952A5 (enExample)
JP2015520161A5 (enExample)
JP2015517488A5 (enExample)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
FI3310809T3 (fi) Anti-cgrp-vasta-aineformulaatio
JP2014503206A5 (enExample)
JP2016501528A5 (enExample)
JP2016539946A5 (enExample)
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
JP2016538885A5 (enExample)
JP2015508771A5 (enExample)
JP2016506416A5 (enExample)
JP2012529436A5 (enExample)
RU2015128078A (ru) Композиции и способы лечения рака мозга
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
JP2013136622A5 (enExample)
JP2017532343A5 (enExample)
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
JP2016517421A5 (enExample)
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same